The psychiatrist used to have to stay with the patient during their entire session. Now they’ll be able to leave the room after administering the drug.
Articles on Psychedelic drugs
Displaying all articles
Psychedelic drug MDMA may help people manage PTSD symptoms. But it should only be used in certain contexts, according to two trauma experts.
Pharmaceutical giants like Johnson & Johnson as well as smaller startups are investing in psychedelic drug development, and both are pursuing FDA approval for their patented psilocybin formulations.
A scholar of religion who is writing a book on sacred drugs explains how today’s ‘psychedelic renaissance’ reflects a millennia-long history of using intoxicants to seek insight and connection.
Receiving a cancer diagnosis and undergoing cancer treatment can be a traumatizing experience. Psychedelics like LSD, psilocybin and MDMA could help alleviate symptoms from cancer-related PTSD.
The early research suggests the drugs might be effective for some conditions. But scientists have safety concerns.
Today’s psychedelics researchers still have to deal with the fallout of the decadeslong freeze on research. Listen to ‘The Conversation Weekly’ podcast.
The TGA is considering a proposal to reclassify psilocybin and MDMA from their current status as prohibited substances. This would allow psychiatrists to use these drugs to treat mental illness.
As the UK’s first clinic to offer psychedelic drugs for mental health disorders opens, a study reveals that informed users don’t have problems with self control.
Ketamine and other psychedelics are being licensed for medical use – two experts advise how to minimise harm for users.
Australia is about to start its first trial of psychedelic drugs for the treatment of anxiety and depression. If the results are positive, this could transform the way we treat mental illness.
Top contributors
-
Emeritus Professor, National Centre for Youth Substance Use Research, The University of Queensland
-
Host, The Conversation Weekly Podcast, The Conversation
-
Postdoctoral Researcher in Child Psychiatry, Vrije Universiteit Amsterdam
-
Honorary Clinical Professor, UCL
-
Research Associate in Psychiatry, University of Cambridge
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Medicinal Chemist, UNSW
-
Professor of Neurology, University of California, San Francisco
-
PhD candidate, University of Sydney
-
Distinguished Professor of Neurology and Psychiatry, Director of Psychedelics Division at Neuroscape, University of California, San Francisco
-
Research fellow, Swinburne University of Technology
-
Associate Science Editor & Co-Host of The Conversation Weekly Podcast, The Conversation
-
Associate Professor in Psychiatry, University of Oxford
-
Goodrich C White Professor of Religion, Emory University
-
Senior Lecturer of Addiction, Edith Cowan University